KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Current Assets (2018 - 2025)

Twist Bioscience (TWST) has disclosed Current Assets for 6 consecutive years, with $489.3 million as the latest value for Q1 2023.

  • On a quarterly basis, Current Assets fell 26.36% to $489.3 million in Q1 2023 year-over-year; TTM through Mar 2023 was $489.3 million, a 26.36% decrease, with the full-year FY2022 number at $596.5 million, up 9.15% from a year prior.
  • Current Assets was $489.3 million for Q1 2023 at Twist Bioscience, down from $596.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $664.4 million in Q1 2022 to a low of $121.0 million in Q1 2019.
  • A 5-year average of $416.1 million and a median of $437.1 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 390.71% in 2020, then plummeted 39.31% in 2021.
  • Twist Bioscience's Current Assets stood at $129.3 million in 2019, then skyrocketed by 390.71% to $634.4 million in 2020, then tumbled by 39.31% to $385.0 million in 2021, then surged by 54.93% to $596.5 million in 2022, then decreased by 17.97% to $489.3 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Current Assets are $489.3 million (Q1 2023), $596.5 million (Q3 2022), and $624.1 million (Q2 2022).